Chart: FDA's November 2008 Clearances of 510(k)s
This article was originally published in The Gray Sheet
Executive Summary
FDA's November 2008 Clearances of 510(k)sYou may also be interested in...
EU Approvals: Evenity Cleared For Severe Osteoporosis
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
IGBA Urges WIPO To Revoke Patent Database Support
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
AAM Criticizes Lower Health Care Costs Act
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: